



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_61_26

I am hoping that you will be able to help me with a Freedom of Information request that I have, can you please help me with the following information.

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

1. Does your Trust treat patients for the two following conditions?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)

Yes.

1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

Waldenström macroglobulinaemia (WM) = 13

Marginal zone lymphoma (MZL) = **

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

Waldenström macroglobulinaemia (WM) = 0

Marginal zone lymphoma (MZL) = 0

2. How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	Total Patients	New Patients*
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	0	0
Bendamustine in combination with rituximab (Known as BR)	0	0
Ibrutinib	**	0
Ibrutinib in combination with rituximab	0	0
Zanubrutinib	7	0
Acalabrutinib	0	0
Chemotherapy (Other than the listed regimens)	0	0
Wait and watch - no active treatment and monitoring only	**	0
Any other treatment (Other than the listed regimens) <i>Rituximab in combination with bortezomib</i>	**	0

***Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**

3. How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)		
Regimen	Total Patients	New Patients*
Bendamustine in combination with rituximab (Known as BR)	0	0
Chlorambucil in combination with rituximab (Known as CR)	0	0
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	**	0
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	**	0
Zanubrutinib	**	0
Stem Cell Transplant	Do not hold – transplant takes place at UHW .	
Wait and watch - no active treatment and monitoring only	**	0
Any other treatment (Other than the listed regimens)	0	0

***Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.**